Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema

Int J Dermatol. 2011 Oct;50(10):1294-5. doi: 10.1111/j.1365-4632.2011.05051.x.


Background: Hereditary angioedema (HAE) is a rare, autosomal dominant disorder caused by a C1-esterase inhibitor (C1-INH) deficiency (type 1) or qualitative defect (type 2). It is characterized by recurrent subcutaneous or submucosal edema attacks in various organs with a frequency from a few attacks to over one hundred attacks per year.

Methods: We report on the treatment of 141 attacks in a patient with hereditary angioedema with the bradykinin B2 receptor antagonist icatibant.

Results: During the entire observation period, efficacy of icatibant was maintained and not altered due to repeated administrations. No systemic or cardiovascular side affects were observed.

Conclusions: In the present case, icatibant proved to be an effective and safe drug for the symptomatic treatment of acute HAE attacks. Its efficacy was not impaired by repeated administrations over a three-year period in this patient.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Bradykinin / administration & dosage
  • Bradykinin / analogs & derivatives*
  • Bradykinin / therapeutic use
  • Bradykinin B2 Receptor Antagonists*
  • Clinical Trials, Phase III as Topic
  • Drug Administration Schedule
  • Hereditary Angioedema Types I and II / drug therapy*
  • Humans
  • Long-Term Care
  • Male
  • Middle Aged
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • Bradykinin B2 Receptor Antagonists
  • icatibant
  • Bradykinin